The use of vaccines in treating cervical cancer: Present status and future prospects

International Journal of Gynecological Cancer

Volumn 9, Issue 4, 1999, Pages 265-278

  Onon, T S ^a   Kitchener, H C ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Cervical cancer; HPV; Vaccines

Indexed keywords

BACTERIAL VACCINE; CANCER VACCINE; CAPSID PROTEIN; PEPTIDE DERIVATIVE; PROTEIN DERIVATIVE; RECOMBINANT VACCINE; VIRUS VACCINE;

CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG EFFICACY; DRUG TARGETING; HUMORAL IMMUNITY; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

EID: 0032803240     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1999.99022.x     Document Type: Review

References (111)

1. Parkin DM. The epidemiological basis for evaluating screening policies. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford: Blackwell Science, 1997; 51-69.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594-606.
3. Kitchener HC, Cruickshank ME, Farmery E. The 1993 British Society for Colposcopy and Cervical Pathology/ National Coordinating Network United Kingdom Colposcopy Survey. Comparison with 1988 and the response to introduction of guidelines. Br J Obstet Gynaecol 1995; 102: 549-52.
4. zur Hausen H. Condylomata acuminata and human genital cancer. Cancer Res 1976; 36: 794.
5. Mackett M, Williamson JD. Human Vaccines and Vaccination. 1st edn. Oxford: BIOS Scientific Publishers Limited, 1995; 48.
6. Sun XW, Ellerbrock TV, Lungu O, Chiasson MA, Bush TJ, Wright TC. Human papillomavirus infection in human immunodeficiency virus-seropositive women. Obstet Gynecol 1995; 85: 680-6.
7. Rezza G, Giuliani M, Branca M, et al. Determinants of squamous intraepithelial lesions (SIL) on Pap smear: The role of HPV infection and of HIV 1-induced immunosuppression. DIANAIDS Collaborative Study Group. Eur J Epidemiol 1997; 13: 937-43.
8. Petry KU, Scheffel D, Bode U, et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer 1994; 57: 836-40.
9. Lutzner MA. Papillomavirus lesions in immunodepression and immunosuppression. Clin Dermatol 1985; 3: 165-9.
10. van Ranst M, Tachezy R, Burk RD. Human papillomaviruses: A neverending story? In: Lacey C, ed. Papillomavirus Reviews: Current Research on Papillomaviruses. Leeds: Leeds University Press, 1996; 1-19.
11. Hildesheim A. Human papillomavirus variants: Implications for natural history studies and vaccine development efforts. J Natl Cancer Inst 1997; 89: 752-3.
12. Wieland U. Pfister H. Papillomaviruses in human pathology: Epidemiology, pathogenesis and oncogenic role. In: Gross GE, Barrasso R, eds. Human Papilloma Virus Infection: A Clinical Atlas. Berlin: Ullstein Mosby GmbH & Co. KG, 1997; 1-18.
13. Cullen AP, Reid R, Campion M, Lorincz AT. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol 1991; 65: 606-12.
14. Jeon S, Lambert PF. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: Implications for cervical carcinogenesis. Proc Natl Acad Sci USA 1995; 92: 1654-8.
15. Crook T, Vousden KH. HPV oncoprotein function. In: Lacey C, ed. Papillomavirus Reviews; Current Research on Papillomaviruses. Leeds: Leeds University Press, 1996; 55-60.
16. von Knebel Doeberitz M, Rittmuller C, Aengeneyndt F, Jansen Durr P, Spitkovsky D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions. J Virol 1994; 68: 2811-21.
17. Pardoll DM. Cancer vaccines. Nature Medicine 1998; 4: 525-31.
18. Stanley M, Coleman N, Chambers M. The host response to lesions induced by human papillomavirus. Ciba Found Symp 1994; 187: 21-44.
19. Syrjänen KJ. Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV). Eur J Obstet Gynecol Reprod Biol 1996; 65: 45-53.
20. Hilders CG, Ras L, van Eendenburg JD, Nooyen Y, Fleuren GJ. Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma. Int J Cancer 1994; 57: 805-13.
21. Nakagawa M, Stites DP, Farhat S, et al. T-cell proliferative response to human papillomavirus type 16 peptides: Relationship to cervical intraepithelial neoplasia. Clin Diagn Lab Immunol 1996; 3: 205-10.
22. Shepherd PS, Rowe AJ, Cridland JC, Coletart T, Wilson P, Luxton JC. Proliferative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia. J Gen Virol 1996; 77: 593-602.
23. Luxton JC, Rowe AJ, Cridland JC, Coletart T, Wilson P, Shepherd PS. Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals. J Gen Virol 1996; 77: 1585-93.
24. de Gruijl TD, Bontkes HJ, Stukart MJ, et al. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. J Gen Virol 1996; 77: 2183-91.
25. Luxton JC, Rose RC, Coletart T, Wilson P, Shepherd PS. Serological and T-helper cell responses to human papillomavirus type 16 L1 in women with cervical dysplasia or cervical carcinoma and in healthy controls. J Gen Virol 1997; 78: 917-23.
26. Kadish AS, Ho GY, Burk RD, et al. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst 1997; 89: 1285-93.
27. de Gruijl TD, Bontkes HJ, Walboomers JMM et al. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: A longitudinal study. Cancer Res 1998; 58: 1700-6.
28. Ressing ME, van Driel WJ, Celis E et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 1996; 56: 582-8.
29. Alexander M, Salgaller ML, Celis E, et al. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E 7 epitope. Am J Obstet Gynecol 1996; 175: 1586-93.
30. Evans C, Bauer S, Grubert T, et al. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. Cancer Immunol Immunother 1996; 42: 151-60.
31. Nakagawa M, Stites DP, Farhat S, et al. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: Relationship to cervical intraepithelial neoplasia. J Infect Dis 1997; 175: 927-31.
32. Nimako M, Fiander AN, Wilkinson GW, Borysiewicz LK, Man S. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res 1997; 57: 4855-61.
33. Evans EM, Man S, Evans AS, Borysiewicz LK. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997; 57: 2943-50.
34. Muller M, Viscidi RP, Sun Y, et al. Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16-associated invasive cervical cancer. Virology 1992; 187: 508-14.
35. Hamsikova E, Novak J, Hofmannova V, et al. Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls. J Infect Dis 1994; 170: 1424-31.
36. Dillner J, Wiklund F, Lenner P, et al. Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. Int J Cancer 1995; 60: 377-82.
37. Dillner J, Lehtinen M, Bjorge T, et al. Prospective seroepidemiological study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 1997; 89: 1293-9.
38. Meschede W, Zumbach K, Braspenning J, et al. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol 1998; 36: 475-80.
39. Fujii T, Matsushima Y, Yajima M, Sugimura T, Terada M. Serum antibody against unfused recombinant E7 protein of human papillomavirus type 16 in cervical cancer patients. Jpn J Cancer Res 1995; 86: 28-34.
40. Chee YH, Namkoong SE, Kim DH, Kim SJ, Park JS. Immunologic diagnosis and monitoring of cervical cancers using in vitro translated HPV proteins. Gynecol Oncol 1995; 57: 226-31.
41. Fisher SG, Benitez-Bribiesca L, Nindl I, et al. The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer. Gynecol Oncol 1996; 61: 73-8.
42. Baay MF, Duk JM, Burger MP, et al. Antibodies to human papillomavirus type 16 E7 related to clinicopathological data in patients with cervical carcinoma. J Clin Pathol 1995; 48: 410-4.
43. Viladiu P, Bosch FX, Castellsague X, et al. Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2 and E7 peptides as predictors of survival in patients with squamous cell cervical cancer. J Clin Oncol 1997; 15: 610-9.
44. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994; 86: 494-9.
45. Nonnenmacher B, Hubbert NL, Kirnbauer R, et al. Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis 1995; 172: 19-24.
46. de Gruijl TD, Bontkes HJ, Walboomers JMM, et al. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective non-intervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst 1997; 89: 630-8.
47. Tindle RW. Human papillomavirus vaccines for cervical cancer. Curr Opin Immunol 1996; 8: 643-50.
48. Robbins JB, Schneerson R, Szu SC. Perspective: Hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995; 171: 1387-98.
49. Brandsma JL. Animal models for human papillomavirus vaccine development. In: Lacey C, ed. Papillomavirus Reviews: Current Research on Papillomaviruses. Leeds: Leeds University Press, 1996; 69-78.
50. Campo MS. Infection by bovine papillomavirus and prospects for vaccination. Trends Microbiol 1995; 3: 92-7.
51. Meneguzzi G, Kieny MP, Lecocq JP, Chambon P, Cuzin F, Lathe R. Vaccinia recombinants expressing early bovine papilloma virus (BPV1) proteins: Retardation of BPV1 tumor development. Vaccine 1990; 8: 199-204.
52. Jarrett WF, Smith KT, O'Neil BW, et al. Studies on vaccination against papillomaviruses: Prophylactic and therapeutic vaccination with recombinant structural proteins. Virology 1991; 184: 33-42.
53. Kimbauer R, Chandrachud LM, O'Neil BW, et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996; 219: 37-44.
54. Lin YL, Borenstein LA, Selvakumar R, Ahmed R, Wettstein FO. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology 1992; 187: 612-9.
55. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69: 3959-63.
56. Jansen KU, Rosolowsky M, Schultz LD, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995; 13: 1509-14.
57. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996; 70: 960-5.
58. Selvakumar R, Borenstein LA, Lin YL, Ahmed R, Wettstein FO. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J Virol 1995; 69: 602-5.
59. Bell JA, Sundberg JP, Ghim SJ, Newsome J, Jenson AB, Schlegel R. A formalin-inactivated vaccine protects against mucosal papillomavirus infection: A canine model. Pathobiology 1994; 62: 194-8.
60. Suzich JA, Ghim SJ, Palmer-Hill, FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci 1995; 92: 11553-7.
61. Schneider JF, McGlennen RC, LaBresh KV, Ostrow RS, Faras AJ. Rhesus papillomavirus type 1 cooperates with activated ras in transforming primary epithelial rat cells independent of dexamethasone. J Virol 1991; 65: 3354-8.
62. Chen LP, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci 1991; 88: 110-4.
63. Chen LP, Mizuno MT, Singhal MC, et al. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 1992; 148: 2617-21.
64. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with a cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242-9.
65. McLean CS, Sterling JS, Mowat J, Nash AA, Stanley MA. Delayed-type hypersensitivity response to the human papillomavirus type 16 E7 protein in a mouse model. J Gen Virol 1993; 74: 239-45.
66. Chambers MA, Stacey SN, Arrand JR, Stanley MA. Delayed-type hypersensitivity response to human papillomavirus type 16 E6 protein in a mouse model. J Gen Virol 1994; 75: 165-9.
67. Kondoh G, Li Q, Pan J, Hakura A. Transgenic models for papillomavirus-associated multistep carcinogenesis. Intervirology 1995; 38: 181-6.
68. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185: 251-7.
69. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci 1992; 89: 12180-4.
70. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993; 67: 315-22.
71. Kirnbauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993; 67: 6929-36.
72. Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 1994; 75: 2075-9.
73. Hines JF, Ghim SJ, Christensen ND, et al. Role of conformational epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination. Gynecol Oncol 1994; 55: 13-20.
74. Dupuy C, Buzoni-Gatel D, Touze A, Le Cann P, Bout D, Coursaget P. Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles. Microb Pathog 1997; 22: 219-25.
75. Muller M, Zhou J, Reed TD, et al. Chimeric papillomavirus-like particles. Virology 1997; 234: 93-111.
76. Greenstone HL, Nieland JD, de Visser KE, et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV 16 tumor model. Proc Natl Acad Sci 1998; 95: 1800-5.
77. Zhou J, Stenzel DJ, Sun XY, Frazer IH. Synthesis and assembly of infectious bovine papillomavirus particles in vitro. J Gen Virol 1993; 74: 763-8.
78. McCarthy MP, White WI, Palmer-Hill F, Koenig S, Suzich JA. Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. J Virol 1998; 72: 32-41.
79. Meneguzzi G, Cerni C, Kieny MP, Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 1991; 181: 62-9.
80. Zhou JA, McIndoe A, Davies H, Sun XY, Crawford L. The induction of cytotoxic T lymphocyte precursor cells by recombinant vaccinia virus expressing human papillomavirus type 16 L1. Virology 1991; 181: 203-10.
81. Zhu X, Tommasino M, Vousden K, et al. Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papillomavirus 16 in H-2d mice. Scand J Immunol 1995; 42: 557-63.
82. Hagensee ME, Carter JJ, Wipf GC, Galloway DA. Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies. Virology 1995; 206: 174-82.
83. Boursnell ME, Rutherford E, Hickling JK, et al. Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 1996; 14: 1485-94.
84. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. New Engl J Med 1969; 281: 1201-8.
85. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347: 1523-7.
86. Nardelli-Haefliger D, Roden RB, Benyacoub J, et al. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 1997; 65: 3328-36.
87. Jensen ER, Selvakumar R, Shen H, Ahmed R, Wettstein FO, Miller JF. Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J Virol 1997; 71: 8467-74.
88. Medaglini D, Oggioni MR, Pozzi G. Vaginal immunization with recombinant gram-positive bacteria. Am J Reprod Immunol 1998; 39: 199-208.
89. Donnelly JJ, Martinez D, Jansen KU, Ellis RW, Montgomery DL, Liu MA. Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis 1996; 173: 314-20.
90. Sundaram P, Tigelaar RE, Xiao W. Brandsma JL. Intracutaneous vaccination of rabbits with the E6 gene of cottontail rabbit papillomavirus provides partial protection against virus challenge. Vaccine 1998; 16: 613-23.
91. Duggan-Keen MF, Brown MD, Stacey SN, Stern PL. Papillomavirus vaccines. Frontiers Biosc 1998; 3: 1192-1208.
92. Kast WM, Brandt RMP, Drijfhout JW, Melief CJM. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunotherapy 1993; 14: 115-20.
93. Kast WM, Brandt RMP, Sidney J, et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994; 152: 3904-12.
94. Melief CJM, Kast WM. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 1995; 145: 167-77.
95. Duggan-Keen MF, Keating PJ, Stevens FRA, et al. Immunogenetic factors in HPV-associated cervical cancer: Influence on disease progression. Eur J Immunogenet 1996; 23: 275-84.
96. Girolomoni G, Ricciardi-Castagnoli P. Dendritic cells hold promise for immunotherapy. Immunol Today 1997; 18: 102-4.
97. Tuting T, DeLeo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol 1997; 27: 2702-7.
98. de Bruijn ML, Schuurhuis DH, Vierboom MP, et al. Immunization with human papillomavirus type 16 (HPV 16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV 16-induced tumor cells. Cancer Res 1998; 58: 724-31.
99. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJM, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 1995; 18: 86-94.
100. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Medicine 1996; 2: 52-8.
101. Steller MA, Gurski KJ, Murakami M, et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998; 4: 2103-9.
102. Christensen ND, Hopfl R, di Angelo SL, et al. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 1994; 75: 2271-6.
103. White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 1998; 72: 959-64.
104. Flannelly G, Langhan H, Jandial L, Mann E, Campbell M, Kitchener H. A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1997; 104: 718-22.
105. Ellis JRM, Keating PJ, Baird J, et al. The association of an HPV 16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nature Medicine 1995; 1: 464-70.
106. Ellis JRM, Etherington I, Galloway D, Luesley D, Young LS. Antibody responses to HPV 16 virus-like particles in women with cervical intraepithelial neoplasia infected with a variant HPV 16. Lancet 1997; 349: 1069-70.
107. Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18:89-95.
108. Keating PJ, Cromme FV, Duggan-Keen M, et al. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995; 72: 405-11.
109. Bontkes HJ, Walboomers JMM, Meijer CJLM, Helmerhorst TJM, Stern PL. Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet 1998; 351: 187-8.
110. Kono K, Maaike ER, Brandt RMP, et al. Decreased expression of signal-transducing ζchain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 1996; 2: 1825-8.
111. Onon TS, Duggan-Keen M, Stern P, Kitchener HC. Expression of signal-transducing zeta (ζ) chains in peripheral blood lymphocytes (PBLs) of women with cervical cancer. Br J Obstet Gynaecol 1998; 105 (Suppl. 17): 94-5.